CD19 and cancer: Using both in vitro assays and tumor studies in immunodeficient mice, we show that HIP engineering does not impact CAR T cell specificity, impair cytotoxic function, accelerate T cell exhaustion, or weaken anti-tumor efficacy against CD19+ Nalm6 and Daudi cancer cells.